CardioACC Launches Global Smallest 7.5F 2D Intracardiac Echocardiography System Clinical Trial and Secures Two Rounds of Financing Within Six Months
CARDIOACC
Developer of Cardiovascular Interventional Imaging Medical Devices
VCBeat has learned at the earliest opportunity that,CARDIOACC (Shenzhen XinHuan Technology Co., Ltd., hereinafter referred to as “CARDIOACC”) has officially launched the registration clinical trial for its 7.5F 2D Intracardiac Echocardiography (ICE) Imaging System, and has sequentially completed clinical enrollment for dozens of cases. The ultrasound catheter of this model is smaller in size than all currently marketed ICE products worldwide,Approaching the limits of industry craftsmanship will help minimize complications caused by puncture injuries and provide patients with high-quality ICE solutions from China.
Meanwhile, the CARDIOACC team has pioneered the development of China’s first 4D ICE system. This system integrates cutting-edge ultrasound imaging technologies, such as soft beamforming and arbitrary waveform transmission, effectively reducing the risks associated with cardiac interventional procedures and shortening the learning curve for operators.
Based on solid business progress,CARDIOACC has garnered strong recognition from investors, successfully closing two rounds of financing totaling tens of millions of RMB within six months. Following its Pre-A round in June 2023, which raised tens of millions of RMB and was led by Luxin Venture Capital with participation from Zhuhai Beiqinghe, the company completed an additional funding round of tens of millions of RMB in December of the same year. This later round was co-led by a fund under Tongfang Investment and a well-known healthcare-focused fund in the industry, with existing shareholder Zhuhai Beiqinghe increasing its investment. Kaicheng Capital served as the financial advisor for multiple consecutive financing rounds.The funds raised will be used for the registration clinical trials of products and the development and iteration of next-generation products.
In recent years, the rapid advancement of percutaneous catheter-based interventional techniques has driven changes in the diagnosis and treatment of structural heart disease, arrhythmias, and other fields. As more complex cardiac procedures are successfully performed, the demands for intraoperative imaging have become increasingly stringent. Previously, interventional procedures typically relied on transesophageal echocardiography (TEE) for guidance; however, this approach presents challenges such as patient tolerance and anesthesia coordination. Intracardiac echocardiography (ICE), with its advantages of real-time imaging, real-time monitoring of intraoperative complications, and good tolerability (without the need for general anesthesia or deep sedation), has achieved global clinical consensus and is now widely adopted.
Multiple clinical studies have demonstrated that intracardiac echocardiography (ICE) enhances the precision and safety of procedures such as radiofrequency ablation for atrial fibrillation and left atrial appendage closure, reduces the risk of procedural complications, shortens operative time, improves patient comfort, and significantly decreases fluoroscopy usage, thereby reducing radiation exposure to both patients and medical staff.
With the continuous implementation of volume-based procurement across China and the successive release of regulatory policies favoring domestically produced medical devices, the interventional ultrasound sector, currently dominated by foreign brands, is poised to witness the rise of a cohort of outstanding Chinese manufacturers.
The founding team of CARDIOACC has focused on the core underlying technologies of ultrasound for many years. Core members primarily come from renowned universities at home and abroad, such as Imperial College London, Johns Hopkins University, and Xi’an Jiaotong University, as well as leading cardiovascular device companies in the industry, including Johnson & Johnson and Acclarent. The team is mature and highly experienced.
Since its establishment in October 2021, the company has been dedicated to developing globally competitive, innovative, domestically produced interventional imaging products, such as 2D ICE and 4D ICE systems. Always centering on unmet critical clinical needs and aligning with China’s healthcare environment that emphasizes cost reduction and efficiency improvement, the company leverages its robust foundational R&D capabilities to achieve continuous breakthroughs. It provides the industry with safe, effective, and cost-controllable solutions for interventional ultrasound devices and consumables, striving steadfastly to become a world-class platform enterprise in the field of interventional ultrasound.
For this financing round,Dr. Zhou Xinhuan, CEO of CARDIOACC“He stated, ‘ICE holds significant clinical value in cardiac interventions, representing the trend toward precise, safe, and eco-friendly procedures, and constitutes a new form of advanced productive force in the current field of ultrasound imaging. CARDIOACC possesses robust foundational R&D capabilities and an efficient, proactive core team. We are committed to developing original, disruptive technologies to drive innovation in interventional ultrasound imaging and contribute to the industry. We also extend our sincere gratitude to both new and existing shareholders for their continued support of CARDIOACC.’”
Related Reading: